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Circulating Interleukin-10 and Risk of
Cardiovascular Events
A Prospective Study in the Elderly at Risk
Paul Welsh, Heather M. Murray, Ian Ford, Stella Trompet, Anton J.M. de Craen, J. Wouter Jukema,
David J. Stott, Iain B. McInnes, Chris J. Packard, Rudi G.J. Westendorp, Naveed Sattar, for the
PROSPER Study Group
Objective—The goal of this study was to examine the association of the antiinflammatory interleukin-10 (IL-10) with risk
of cardiovascular disease (CVD).
Methods and Results—In the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) cohort, we related
baseline concentrations of circulating IL-10 to risk of CVD events in a nested case (n819)-control (n1618) study of
3.2 years of follow-up. Circulating IL-10 showed few strong associations with classical risk factors but was positively
correlated with IL-6 and C-reactive protein. IL-10 was positively associated with risk of CVD events (odds ratio [OR]
1.17, 95% CI 1.05 to 1.31 per unit increase in log IL-10) after adjusting for classical risk factors and C-reactive protein.
Furthermore, IL-10 was associated more strongly with CVD risk among those with no previous history of CVD (OR
1.42, 95% CI 1.18 to 1.70), compared with those with previous CVD (OR 1.04, 95% CI 0.90 to 1.19; P0.018). Overall,
IL-10 showed a modest ability to add discrimination to classical risk factors (C-statistic 0.005, P0.002).
Conclusion—Baseline circulating levels of the antiinflammatory IL-10 are positively associated with risk of CVD among
the elderly without prior CVD events, although the association is less evident in those with a history of CVD. Additional
epidemiological and mechanistic studies investigating the role of IL-10 in CVD are warranted. (Arterioscler Thromb
Vasc Biol. 2011;31:2338-2344.)
Key Words: cardiovascular disease prevention  cytokines  epidemiology  risk factors  inflammation
Interleukin-10 (IL-10) is a pleiotropic cytokine that isproduced by a variety of immunologic cells, including
Th2-type T cells, some T-regulatory cells, B cells, and
macrophages, and is most widely recognized as an antiin-
flammatory cytokine.1,2 It mediates this antiinflammatory
action primarily by inhibiting Th1-type T-cell cytokine pro-
duction, antigen presentation, and proliferation,3 and it plays
a role in limiting macrophage inflammatory responses.4
In keeping with an antiinflammatory role, IL-10 may be an
antiatherogenic cytokine. Overexpression of IL-10 locally,
systemically, or by activated T-cells reduces atherosclerosis
development in mouse models,5,6 and IL-10 deficient athero-
sclerosis-prone mice more rapidly develop plaques with a
phenotype conducive to rupture compared with control
mice.7,8 This effect of IL-10 is in direct contrast to classically
proinflammatory cytokines, such as IL-6 and interferon ,
which may exacerbate atherogenesis in similar mouse mod-
els.9 In humans, unstable atherosclerotic plaques have appar-
ently greater localized IL-10 expression in immunostained
atherectomy specimens than stable plaques.10
In epidemiological studies, many proinflammatory cyto-
kines and inflammatory biomarkers (such as IL-6) are posi-
tively associated with risk of cardiovascular disease (CVD).11
Consequently, one may hypothesize that circulating IL-10 is
inversely associated with CVD (in line with an antiathero-
genic role). However, in small clinical studies, IL-10 levels
have been reported to be unchanged,12,13 increased,14,15 or
decreased16,17 in stable and unstable angina patients relative
to controls. Additionally complicating matters, higher circu-
lating IL-10 has been reported to be associated with im-
proved18,19 and worsened20 prognosis in patients with acute
coronary syndromes. Large prospective studies examining the
association of circulating IL-10 with CVD risk are hence
required. In a recent prospective study (the Estrogen and
Replacement and Atherosclerosis study of middle-aged
women with prevalent atherosclerosis) there was a positive
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association of circulating levels IL-10 with risk of coronary
heart disease (CHD), such that a 1 standard deviation increase
in IL-10 was associated with a hazard ratio of 1.34 (95% CI
1.06 to 1.68) for CHD, although this study was based on only
71 CHD events, an outcome that included angina.21 There is
hence a need for more rigorous epidemiological assessment
of the link between IL-10 and CVD risk to more clearly
understand the etiologic relevance of the circulating IL-10
biomarker signal. Furthermore, it would be useful to test for
the first time whether IL-10 measurements have any clinical
potential in risk prediction.
In PROSPER (PROspective Study of Pravastatin in the
Elderly at Risk),22 we have substantial power in terms of end
points, and hence the potential to explore for differential
associations of IL-10 with subsequent prespecified vascular
events (including fatal versus nonfatal events) and its asso-
ciations in primary versus secondary prevention groups.
Moreover, we were also able to examine whether such
associations were independent of traditional risk factors, as
well as C-reactive protein (CRP).
Methods
Participants
The use of the PROSPER trial as a post hoc cohort study for the
prospective investigation of inflammatory factors as CVD risk
markers has been previously described.23 Men and women aged 70
to 82 years were recruited between December 1997 and May 1999 if
they had either preexisting vascular disease (coronary, cerebral, or
peripheral) or raised risk of such disease because of smoking,
hypertension, or diabetes. Further inclusion criteria included total
cholesterol between 4.0 and 9.0 mmol/L (135 to 350 mg/dL) and
fasting triglyceride concentrations less than 6.0 mmol/L (534 mg/
dL). Participants were randomly assigned to receive either 40 mg of
pravastatin daily or matching placebo. All subjects were clinically
examined at baseline before randomization, which included drawing
of venous blood samples and measurement of body mass index
(BMI) (weight/height2) and blood pressure, among other clinical
parameters, by health professionals.22 The institutional ethics review
boards of all centers approved the protocol, and all participants gave
written informed consent. The protocol was consistent with the
Declaration of Helsinki. All data were processed and analyzed at the
Robertson Centre for Biostatistics, University of Glasgow (Glasgow,
United Kingdom). In the original PROSPER trial, there were 881
primary end points (definite or suspected death from CHD, nonfatal
myocardial infarction, and fatal or nonfatal stroke) over 3.2 years of
follow-up of 5804 elderly participants at elevated CVD risk. A
blinded end points committee reviewed and adjudicated all incident
vascular end points, including all possible strokes.22 In the present
study, to maximize efficiency, we matched all available primary end
point cases to 2 controls selected at random from those in the cohort
who did not experience a primary end point during the follow-up,
and we analyzed IL-10 levels in available plasma samples with
sufficient residual volume.
Laboratory Analysis
Baseline classical CVD risk factors, BMI, and inflammatory markers
were measured as previously reported.22–24 IL-10 was assayed on a
saved biobank of baseline plasma samples on a commercially
available ELISA (R&D Systems, Oxford, United Kingdom), with a
reported interassay coefficient of variation of 4.5%. All samples
were processed by technicians blinded to the identity of samples, and
results were entered into a master database of which the PROSPER
statistics division in Scotland (Robertson Centre, University of
Glasgow) is custodian.
Statistical Analysis
Baseline variables were summarized as mean (SD) for continuous
variables and as number (percentage) for categorical variables.
Where necessary (eg, for IL-10), continuous variables were trans-
formed logarithmically to give a near-normal distribution of data for
parametric analysis. Statistical analyses included calculation of the
univariate conditional logistic regression odds ratio (OR) for baseline
characteristics, for primary end point with controls, and in subse-
quent subgroup analysis (primary versus secondary prevention, fatal
versus nonfatal CVD events, and for analysis of subgroups by
median baseline IL-10 and IL-6). The OR for continuous variables
was calculated for a 1-unit increase in log IL-10. C-statistics were
calculated for the Cox proportional hazards survival models25
containing classical risk factors with and without addition of log
IL-10 and then log CRP and are reported along with resultant
probability values testing whether the inclusion of log IL-10 and log
CRP leads to predictions that are more concordant with observed
events. Data were analyzed using the SAS version 9.1 (SAS Institute
Inc., Cary, NC) and TIBCO Spotfire S version 8.1 (TIBCO
Software Inc) software packages.
Results
Sample Availability
Because of sample attrition from previous studies, there were
819 primary end point (case) samples and 1618 control
samples that had sufficient plasma for IL-10 measurement
(92.2% of the total), with no evidence of a higher degree of
missingness among cases versus controls (P0.16) or in
primary versus secondary prevention (P0.15). Missing
samples were therefore missing at random.
Baseline Risk Factors
For conventional risk factors, the case and control popula-
tions had differences similar to those expected based on
results from the whole cohort23 (Table 1); cases were slightly
older than controls, were more likely to be male, had lower
total cholesterol (which was apparently driven by a lower
high-density lipoprotein cholesterol), were more likely to
be smokers, had greater prevalence of history of vascular
disease and diabetes at baseline, and were less likely to be
randomly assigned to pravastatin at baseline. Circulating
IL-10 concentrations were higher among cases (geometric
mean 3.06 pg/mL [standard deviation 2.27]) than con-
trols (2.75 pg/mL [2.20 pg/mL]; P0.0025) on univari-
able comparison (Table 1).
Correlations of IL-10 With CVD Risk Factors
IL-10 had limited associations with classical CVD risk
factors; there was no evidence of an association with age,
blood pressure, low-density lipoprotein cholesterol, BMI,
smoking, diabetes, or history of CHD or stroke (Table 2).
There was a weak inverse association of IL-10 with HDL-
cholesterol (r0.067; P0.0072) and log CRP (r0.097;
P0.0001) and a moderate association with log IL-6
(r0.161; P0.0001). Males had slightly higher levels of
IL-10 than females (P0.002), and IL-10 levels were higher
in the Netherlands than in Scotland or Ireland (P0.0001).
IL-10 Associations With CVD Risk
IL-10 was positively associated with risk of a primary end
point among all participants (OR 1.18 [95% confidence
interval, 1.06 to 1.32]) (Table 3). This OR was virtually
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unchanged after adjusting for conventional risk factors or for
conventional risk factors plus CRP (1.17 [1.05 to 1.31]).
When the population was split by treatment randomization
(as was performed in previous PROSPER analysis, with no
identifiable interaction for inflammatory markers23), the pos-
itive association of baseline IL-10 with risk of primary end
point was still evident in placebo recipients but not in
pravastatin recipients. This finding was consistent both in the
unadjusted and in the fully adjusted analysis (OR 1.31 [1.10
to 1.58] in placebo recipients versus 1.06 [0.91 to 1.24] in
statin recipients the later model; P for interaction0.031).
The link between IL-10 and outcomes was similar for CHD
death versus nonfatal myocardial infarction (Table 3).
Because of a potential for reverse causality, we examined
the association of IL-10 with risk of CVD in those with and
without history of prior CVD (Table 4). Among those with no
history of CVD, circulating IL-10 levels were associated with
the primary end point (regardless of treatment of group) in the
fully adjusted model (OR 1.42 [1.18 to 1.70]) in all partici-
pants. However, IL-10 was not associated with risk of
primary end point in those with a history of CVD events (1.04
[0.90 to 1.19). These 2 associations showed significant
interaction (P0.018).
To further investigate whether IL-10 is positively or
negatively associated with CVD risk in the context of
ongoing inflammation, we devised a model splitting the
cohort into high and low IL-10 and IL-6 categories by the
median observed value of each marker (2.97 and 2.51
pg/mL, respectively) (Supplemental Data, available online at
Table 1. Comparison of Baseline Characteristics Between
Cases and Controls
Cases
(n819)
Controls
(n1618) P Value
Continuous variables, mean (SD)
Age, y 75.7 (3.5) 75.4 (3.3) 0.011
Body mass index, kg/m2 26.9 (4.1) 26.8 (4.1) 0.96
Systolic blood pressure, mm Hg 154.9 (22.7) 154.0 (21.4) 0.33
Diastolic blood pressure, mm Hg 82.9 (11.8) 83.6 (11.4) 0.14
Total cholesterol, mmol/L 5.61 (0.86) 5.68 (0.92) 0.046
HDL cholesterol, mmol/L 1.24 (0.34) 1.28 (0.33) 0.0067
LDL cholesterol, mmol/L 3.74 (0.76) 3.79 (0.81) 0.15
Triglyceride, mmol/L* 1.43 (1.54) 1.42 (1.52) 0.37
IL-10, pg/mL* 3.06 (2.27) 2.75 (2.20) 0.0025
Categorical variables, n (%)
Pravastatin 377 (46.0) 813 (50.2) 0.049
Male 473 (57.8) 761 (47.0) 0.0001
Smoking 0.036
Never 254 (31.0) 573 (25.4)
Current smoker 222 (27.1) 448 (27.7)
Ex smoker 254 (31.0) 597 (36.9)
Country 0.0001
Scotland 333 (40.7) 685 (42.3)
Ireland 369 (45.0) 606 (37.4)
Netherlands 117 (14.3) 327 (20.2)
History of:
Diabetes 123 (15.0) 177 (10.9) 0.0038
Hypertension 494 (60.3) 1003 (62.0) 0.42
Coronary disease 357 (43.6) 470 (29.0) 0.0001
Peripheral arterial disease 131 (16.0) 164 (10.1) 0.0001
Any vascular disease 459 (56.0) 662 (40.9) 0.0001
P values for continuous variables are from two-sample t test, and P values
for categorical variables are from the 2 test. n is the maximum number. All
available data were used. Please note that because of the design structure of
the trial—recruiting more subjects with hypertension/smokers and subjects
with diabetes (and women) into the low-risk primary prevention group—the
significance or nonsignificance of univariate comparisons in this table could be
potentially misleading. HDL indicates high-density lipoprotein; LDL, low-density
lipoprotein; IL, interleukin.
*Values are geometric means (SD) calculated from the log-transformed
distribution.
Table 2. Associations of Log IL-10 With CVD Risk Factors
Among Controls
Continuous Variables
(Univariable Pearson Correlation) n R P Value
Age, y 1618 0.0004 0.99
Systolic BP, mm Hg 1618 0.009 0.71
Diastolic BP, mm Hg 1618 0.009 0.71
Total cholesterol, mmol/L 1618 0.002 0.93
HDL cholesterol, mmol/L 1618 0.067 0.0072
LDL cholesterol, mmol/L 1618 0.009 0.73
Log Triglycerides, mmol/L 1618 0.032 0.20
BMI, kg/m2 1618 0.002 0.94
Log CRP, mg/dL 1618 0.097 0.0001
Log IL6, pg/mL 1618 0.161 0.0001
Categorical Variables* n Mean (SD) P Value
Sex 0.0020
Male 761 2.94 (2.25)
Female 857 2.60 (2.16)
Country
Scotland 685 2.65 (2.43) Referent
Ireland 606 2.62 (2.10) 0.85
Netherlands 327 3.27 (1.87) 0.0001
Diabetes 0.97
Yes 177 2.75 (2.30)
No 1441 2.75 (2.20)
Smoking
Nonsmoker 573 2.71 (2.01) Referent
Current smoker 448 2.75 (2.13) 0.74
Ex-smoker 597 2.79 (2.45) 0.51
History of CHD 0.45
Yes 470 2.82 (2.62)
No 1148 2.73 (2.04)
History of stroke/TIA 0.25
Yes 162 2.95 (2.06)
No 1456 2.73 (2.22)
IL indicates interleukin; CVD, cardiovascular disease; BP, blood pressure;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive
protein; CHD, coronary heart disease; TIA, transient ischemic attack.
*P values are from 2-sample t tests.
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http://atvb.ahajournals.org). Relative to those with low levels
of both IL-6 and IL-10, those with elevated levels of either or
both cytokines were at increased risk of CVD in the model of
all participants. These observations of increased risk in every
group where cytokine concentrations were elevated were
consistent in the model restricted to those with no history of
CVD (Supplemental Data). However, increases in risk were
less pronounced among those with a history of CVD (con-
sistent with the results from Table 4) (Supplemental Data).
Finally, if those with high IL-10 and low IL-6 were used as
the referent (assuming this reflects an “antiinflammatory”
profile), those with low IL-10 and high IL-6 had relative odds
of CVD close to unity: OR 0.98 (95% CI 0.76 to 1.26) among
all participants, OR 0.87 (95% CI 0.60 to 1.27) among those
with no history of CVD, and OR 1.14 (95% CI 0.79 to 1.64)
among those with no history of CVD.
IL-10 in CVD Risk Prediction
Among all participants, the classical risk factors (age, sex,
country, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, systolic blood pressure, smoking,
BMI, history of diabetes, history of hypertension, and base-
line treatment allocation) yielded a C-statistic of 0.592.
Addition of IL-10 to the model increased the C-statistic
marginally, but statistically significantly, by 0.005 (to
0.597, P0.002), and further addition of CRP again only
slightly improved the model including IL-10 by 0.005 (to
0.602, P0.0001 versus the basic model). Restricting the
Table 3. Unadjusted and Adjusted Conditional Logistic Regression Analysis for Baseline IL-10 and the Risk of a Coronary or
Stroke Event
CVD Event Type Events
Unadjusted Adjusted* Adjusted†
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Primary end point
All‡ 819 1.18 (1.06,1.32) 0.0027 1.19 (1.06,1.32) 0.0023 1.17 (1.05,1.31) 0.0049
Placebo 442 1.34 (1.14,1.58) 0.0003 1.33 (1.13,1.57) 0.0008 1.31 (1.10,1.54) 0.0018
Pravastatin 377 1.05 (0.91,1.22) 0.51 1.07 (0.92,1.24) 0.39 1.06 (0.91,1.24) 0.44
CHD death or nonfatal MI
All‡ 588 1.17 (1.03,1.32) 0.014 1.17 (1.03,1.32) 0.017 1.15 (1.01,1.31) 0.030
Placebo 324 1.36 (1.13,1.62) 0.0009 1.35 (1.21,1.63) 0.0016 1.32 (1.10,1.60) 0.0033
Pravastatin 264 1.00 (0.84,1.20) 0.98 1.00 (0.84,1.20) 0.99 0.99 (0.83,1.19) 0.93
Fatal or nonfatal stroke
All‡ 231 1.23 (1.04,1.47) 0.019 1.22 (1.02,1.46) 0.031 1.20 (1.00,1.43) 0.047
Placebo 118 1.32 (10.0,1.71) 0.040 1.25 (0.96,1.63) 0.099 1.23 (0.94,1.61) 0.13
Pravastatin 113 1.17 (0.92,1.48) 0.20 1.20 (0.94,1.53) 0.15 1.19 (0.93,1.52) 0.17
Fatal or nonfatal events
CHD death
All‡ 153 1.29 (1.04,1.61) 0.022 1.22 (0.98,1.52) 0.077 1.17 (0.94,1.46) 0.16
Placebo 92 1.36 (1.02,1.83) 0.039 1.27 (0.95,1.70) 0.11 1.23 (0.92,1.65) 0.17
Pravastatin 61 1.22 (0.88,1.71) 0.23 1.19 (0.85,1.68) 0.31 1.14 (0.80,1.62) 0.49
Nonfatal MI
All‡ 435 1.13 (0.98,1.29) 0.093 1.14 (0.99,1.31) 0.071 1.13 (0.98,1.30) 0.087
Placebo 232 1.35 (1.10,1.65) 0.0039 1.36 (1.10,1.67) 0.0041 1.34 (1.09,1.66) 0.0062
Pravastatin 203 0.95 (0.78,1.15) 0.58 0.94 (0.78,1.15) 0.56 0.94 (0.77,1.15) 0.55
Fatal stroke
All‡ 27 1.11 (0.68,1.82) 0.67 0.95 (0.58,1.56) 0.83 0.90 (0.54,1.50) 0.69
Placebo 11 0.81 (0.42,1.56) 0.53 0.76 (0.36,1.57) 0.46 0.77 (0.37,1.62) 0.49
Pravastatin 16 1.38 (0.76,2.54) 0.29 1.00 (0.54,1.89) 0.99 0.91 (0.46,1.78) 0.78
Nonfatal stroke
All‡ 204 1.25 (1.04,1.51) 0.0017 1.24 (1.03,1.50) 0.026 1.23 (1.02,1.48) 0.035
Placebo 107 1.40 (1.06,1.83) 0.017 1.31 (0.99,1.74) 0.061 1.29 (0.97,1.71) 0.082
Pravastatin 97 1.14 (0.89,1.48) 0.30 1.19 (0.92,1.54) 0.19 1.19 (0.92,1.54) 0.20
Odds ratios are for a 1-unit increase in log IL-10. IL indicates interleukin; CVD, cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction.
*Adjusted for age, sex, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log triglyceride, systolic blood pressure, diastolic blood pressure,
body mass index, smoking status, diabetes, use of antihypertensive therapy, previous CVD (CHD, peripheral arterial disease, stroke, and transient ischemic attack),
and country.
†Also adjusted for log C-reactive protein.
‡Also adjusted for randomized treatment allocation.
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analysis to primary end points only yielded C-statistics that
were broadly similar to the all-subjects analysis: C-statistics
were 0.608, 0.619 (P0.0023), and 0.622 (P0.0002),
respectively.
Discussion
These prospective data in the powerful PROSPER study
allow several important observations regarding circulating
IL-10 concentrations and risk of CVD. First, we confirmed
and extended previous data based on smaller event num-
bers in a population at risk for CVD21 by demonstrating
circulating IL-10 to be independently and positively associ-
ated with increased risk of CVD in the overall cohort. There
was also evidence that IL-10 was a stronger marker of CVD
risk in those without prior CVD. Indeed, IL-10 was associ-
ated with increased risk of CVD (regardless of treatment) in
those without history of CVD, whereas it was not associated
with risk in those who had previously experienced a myocar-
dial infarction or stroke (regardless of treatment). By splitting
the cohort on the basis of baseline median concentrations of
IL-10 and IL-6, we showed that, generally, elevation of either
or both cytokines is associated with an increased risk of CVD.
Finally, we showed that IL-10 may have modest clinical
utility based on incremental information to the C-statistic
for conventional risk factors, although this requires further
investigation.
Overall, these results suggest that the epidemiological
signal for relative risk given by circulating IL-10 is complex
and is likely to be highly context dependent. In many ways,
this makes sense from what is known of basic IL-10 biology.
IL-10 is believed to be a potentially important cytokine in
terms of regulating inflammation within arterial plaques,
where it appears to act in an antiinflammatory manner.1,2,5–8
IL-10 modulates proinflammatory cytokine production, in
particular the Th-1 cytokines typical of atherogenesis2; it may
modulate endothelial function and leukocyte recruitment in
vivo in proinflammatory conditions26; it may influence anti-
gen presentation (including oxidized lipids) from macro-
phages and dendritic cells2; and it may even stabilize rupture-
prone plaques by suppressing apoptotic pathways in foam
cells.27 From this, some investigators may hypothesize an
inverse association of circulating IL-10 with CVD risk.
However, enhanced expression of a true “antiinflammatory”
cytokine makes much more sense in the context of ongoing
inflammation within the tissue, as a counterregulatory mech-
anism to arrest and limit further inflammation. Consistent
with this, circulating IL-10 is positively associated with IL-6
and CRP. Furthermore elevation of IL-10, with or without
elevation in IL-6, is associated with an increased risk of CVD.
Thus, although it is an antiinflammatory cytokine, circulating
IL-10 may be a surrogate marker of ongoing systemic
inflammation and related pathophysiological processes, and it
may be acting to buffer or counterregulate proinflammatory
vascular effects. Furthermore, it must be taken into consid-
eration that the inflammation-driven circulation of cytokines
is a dynamic process and as such will not result in consistent
expression of cytokines; expression of cytokines will have
some fluidity, a process not fully captured by taking blood at
1 baseline time point. In addition, elevation of counterregu-
latory IL-10 may reflect the presence of other proinflamma-
tory cytokines that are associated with CVD risk but that we
have not measured, such as IL-18.28
When the population was split by treatment randomization
(as was performed in previous PROSPER analysis, with no
identifiable interaction for inflammatory markers23), the re-
sults showed that IL-10 was associated with risk in the
placebo group but not in the group on treatment. It is possible
that pravastatin reduces risk of CVD to a greater extent in
those with elevated circulating IL-10 compared with those
with lower IL-10, which would explain our observation.
However, there are sparse data in the literature that may
support this possibility, although Ridker et al have previously
reported in a nested-case-control study from the CARE trial
of pravastatin that CRP and serum amyloid A concentrations
Table 4. Unadjusted and Adjusted Conditional Logistic Regression Analysis for Baseline IL-10 and the Risk of a Coronary or
Stroke Event
Events
Unadjusted Adjusted* Adjusted†
Odds Ratio
(95% CI) P Value
Odds Ratio
(95% CI) P Value
Odds Ratio
(95% CI) P Value
No history of CVD
All‡ 360 1.38 (1.15,1.64) 0.0004 1.44 (1.20, 1.72) 0.0001 1.42 (1.18, 1.70) 0.0002
Placebo 188 1.47 (1.14, 1.89) 0.0025 1.45 (1.12, 1.88) 0.0046 1.44 (1.11, 1.87) 0.0059
Pravastatin 172 1.29 (1.00, 1.65) 0.046 1.41 (1.08, 1.83) 0.010 1.38 (1.06, 1.80) 0.016
History of CVD
All‡ 459 1.06 (0.93, 1.21) 0.40 1.05 (0.91, 1.21) 0.49 1.04 (0.90, 1.19) 0.60
Placebo 254 1.23 (1.00, 1.52) 0.050 1.22 (0.98, 1.52) 0.072 1.18 (0.95, 1.48) 0.13
Pravastatin 205 0.94 (0.78, 1.12) 0.48 0.91 (0.75, 1.10) 0.32 0.91 (0.75, 1.10) 0.31
The primary end point was coronary heart disease death or nonfatal myocardial infarction and fatal or nonfatal stroke. Odds ratios are for a 1-unit increase in log
IL-10. IL indicates interleukin.
*Adjusted for age, sex, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log triglyceride, systolic blood pressure, diastolic blood pressure,
body mass index, smoking status, diabetes, use of antihypertensive therapy, and country.
†Also adjusted for log C-reactive protein.
‡Also adjusted for randomized treatment allocation.
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were related to risk of CHD in those assigned to placebo
(relative risk2.11, P0.048) but not among those randomly
assigned to pravastatin (relative risk1.29, P0.5).29 In
PROSPER, this effect modification by treatment group was
no longer evident after also stratifying by history of CVD.
Given that we have not observed an association of other
inflammatory markers with CVD risk, only in placebo recip-
ients in PROSPER, we suggest that this may be a chance
finding. Additional epidemiological studies in statin trial
cohorts may be useful to expand on our findings.
The positive association of IL-10 with CVD risk was much
stronger among those with no history of CVD events. This is
perhaps not entirely surprising given that classical risk factors
are better predictors of risk among those without history of
CVD in this elderly at risk group. Apart from this simplistic
epidemiological observation, is it possible to explain why
IL-10 is apparently a poor predictor of risk among those who
have a history of CVD? It has been observed that cultured
peripheral blood monocytes taken from acute myocardial
infarction patients and unstable angina patients have mark-
edly reduced potential to express IL-10 in response to
lipopolysaccharide or tumor necrosis factor- stimulation
relative to stable angina patients or healthy controls.30 Those
results are in agreement with epidemiological findings from
the Leiden-85 study of incident stroke.31 These intriguing
observations require further study.
Limitations of the data require consideration. This
PROSPER analysis was based on a nested case-control study
and thus did not include all control samples available. This
may have reduced statistical power but likely only minimally,
given that we had more than 800 cases and more than 1600
controls. Nested case-control is more efficient and cost
effective than measuring novel biomarkers on an entire
cohort and, if conducted well, is unlikely to introduce
biases.32 Frozen sample storage at 80°C before analysis of
IL-10 may have resulted in some degradation of the detect-
able IL-10 signal, although even if this was true, we have no
reason to believe any degradation would be proportionally
different between cases and controls. Moreover, there are
some limited data projecting that IL-10 will be stable for
many years in frozen serum.33 Our observed association of
IL-10 with proinflammatory markers also suggests that the
signal we have detected is biologically relevant. We did not
adjust for regression dilution because of lack of repeat
measurement of IL-10, although this does not alter the
primary implications of our findings. PROSPER comprises
elderly at-risk patients, and we cannot exclude the possibility
that this group may show some differences in association of
inflammation markers with CVD events as compared with
studies in middle-aged populations. However, the observed
adjusted risk associations of IL-6 and CRP with primary
CVD end point23 are broadly consistent with findings from
recent relevant major metaanalyses that also incorporated
younger populations.34,35 Although PROSPER has a high-
vascular-risk population, participants were otherwise clini-
cally healthy, as per trial exclusion criteria.22 The study only
had up to an average of 3.2 years of follow-up, although short
follow-up may be appropriate in elderly populations. The
study is more relevant to reveal novel associations than to test
predictions in general populations, and for this reason we
have not given net-reclassification or integrated discrimina-
tion indexes in the present report. However, given the limited
and context-dependent association of IL-10 with CVD risk
and limited improvement in the C-statistic, we believe a
conclusion that IL-10 is likely to have limited clinical utility
to predict CVD risk is justified by the available data. Finally,
although we can speculate about the mechanisms, our results
in isolation cannot prove or disprove any physiological role
for IL-10 in CVD risk.
In conclusion, IL-10 is positively associated with risk of
CVD among the elderly without history of CVD events, but
this association is weaker in patients with a history of CVD
events. Additional studies on IL-10 in relation to incident
CVD events in younger cohorts appear to be warranted, as
well as mechanistic exploration of our findings, particularly
to examine whether IL-10 is acting to counter proinflamma-
tory vascular processes.
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Figure I: Association of IL-10 and IL-6 with risk of CVD by dichotomous cutoff at the median observed concentration of each cytokine, 
relative to the low IL-10 low IL-6 groups. Figures given for each observation correspond to: odds ratio (95% CI); N=controls, n= cases.
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